Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation

Keyphrases

• Cost-effectiveness 100%
• Non-valvular Atrial Fibrillation 100%
• Quality-adjusted Survival 100%
• Antithrombotic Therapy 100%
• Preference-based 100%
• Atrial Fibrillation 50%
• Risk Factors for Stroke 50%
• Medical Expenditure 50%
• Warfarin 37%
• Incremental Risk 37%
• Aspirin 25%
• Patient Preference 25%
• Quality-adjusted Life Years 25%
• Lifesaving 25%
• Hypertension 12%
• Older Patients 12%
• Stroke History 12%
• Treatment Strategy 12%
• Stroke Risk 12%
• Transient Ischemic Attack 12%
• Heart Disease 12%
• Diabetes Disease 12%
• Decision Analysis 12%
• Atrial Fibrillation Treatment 12%
• Stroke Risk Factors 12%

Medicine and Dentistry

• Cost-Effectiveness Analysis 100%
• Atrial Fibrillation 100%
• Antithrombotic Therapy 100%
• Preference 100%
• Apoplexy 77%
• Warfarin 33%
• Acetylsalicylic Acid 22%
• Patient Preference 22%
• Quality Adjusted Life Year 22%
• Base 11%
• Diabetes 11%
• Heart Disease 11%
• Contraindication 11%
• Transient Ischemic Attack 11%

Nursing and Health Professions

• Cost Effectiveness Analysis 100%
• Atrial Fibrillation 100%
• Anticoagulant Agent 100%
• Cerebrovascular Accident 87%
• Warfarin 37%
• Quality Adjusted Life Year 25%
• Patient Preference 25%
• Base 12%
• Practice Guideline 12%
• Heart Disease 12%
• Transient Ischemic Attack 12%
• Contraindication 12%